Telehealth Stepped Care for Child and Adolescent Mental Health

November 11, 2026 updated by: Child Mind Institute

Stratified Stepped Care Telehealth Care Pathways for Child and Adolescent Mental Health

This study will evaluate a telehealth-delivered stepped-care model to improve access to mental health support for children and adolescents in Brazil and South Africa. The study will include children and adolescents aged 6 to 18 years who have concerns related to anxiety, depression, irritability, or disruptive behavior.

Participants will first complete an online mental health assessment. Depending on their symptom level, they may receive psychoeducational materials, a brief single-session intervention, or additional mental health support. Participants whose symptoms remain elevated after the single-session intervention may be randomly assigned to one of three groups: four-session cognitive behavioral therapy, twelve-session cognitive behavioral therapy, or more intensive psychoeducational materials.

The study will compare changes in mental health symptoms across the three groups. It will also evaluate whether the interventions are acceptable, feasible, safe, and suitable for delivery through telehealth. Participants will complete assessments at baseline, during treatment, after treatment, and approximately six months later.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a multicountry, randomized, open-label, three-arm clinical trial evaluating a stepped-care telehealth model for child and adolescent mental health in Brazil and South Africa.

The study will recruit children and adolescents aged 6 to 18 years and their caregivers. Depending on age and symptom domain, assessments and interventions may be completed by the child or adolescent, the primary caregiver, or both. The study will address symptoms of anxiety, depression, and disruptive or oppositional behavior.

The study includes sequential phases. In the initial phase, participants will complete an online assessment using the LUMI Global measure and related measures. Participants with low or subclinical symptom levels will receive psychoeducational materials. Participants with subclinical symptoms may be reassessed after approximately four weeks. Participants with elevated symptoms will be invited to receive a brief, single-session intervention delivered remotely by trained personnel.

Approximately one week after the single-session intervention, participants will complete a follow-up assessment. Participants whose symptoms remain at a clinically elevated level and who meet the criteria for the next stage of care will be randomized in a 1:1:1 ratio to one of three groups:

  1. - Four-session cognitive behavioral therapy delivered by telehealth;
  2. - Twelve-session cognitive behavioral therapy delivered by telehealth; or
  3. - Enhanced psychoeducational materials without therapist-delivered cognitive behavioral therapy.

The cognitive behavioral therapy protocols will be directed toward the participant's predominant symptom domain, which may include anxiety, depression, or disruptive behavior. The interventions will be adapted for the relevant age group and country while maintaining the core components of the study protocols.

The primary outcome will be treatment response at 12 weeks after randomization, defined as a reduction of at least 50% in symptoms measured with domain-specific instruments. Secondary outcomes will include symptom change at four weeks and six months, functioning, participant and caregiver satisfaction, acceptability, engagement, treatment completion, intervention fidelity, safety, and adverse effects.

All interventions will be delivered remotely through telehealth.

Study Type

Interventional

Enrollment (Estimated)

4000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazil, 90035-903
        • Hospital de Clínicas de Porto Alegre (HCPA)
        • Contact:
        • Principal Investigator:
          • Luis Augusto Rohde, MD, PhD
    • Western Cape
      • Cape Town, Western Cape, South Africa
        • South African Medical Research Council (SAMRC)
        • Contact:
        • Contact:
        • Principal Investigator:
          • Carrie Brooke-Sumner, PhD
        • Sub-Investigator:
          • Jason Bantjes, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Be children or adolescents aged 6 to 18 years living in Brazil or in the participating regions of South Africa, including the Western Cape or KwaZulu-Natal;
  • Have concerns related to emotional or behavioral symptoms, including anxiety, depressed mood, irritability, oppositionality, aggression, or other significant behavioral difficulties;
  • Be able to communicate in a language supported by the study team and intervention materials;
  • Have informed consent from a parent or legal guardian when required and provide assent when applicable. Participants who are legally adults will provide their own informed consent.

Eligibility for each study pathway will be determined sequentially:

  • Participants will first complete the LUMI Global assessment.
  • Participants with low or subclinical symptoms will receive psychoeducational materials. Participants with subclinical symptoms may be reassessed after approximately four weeks.
  • Participants with symptom scores at or above 1.5 standard deviations above the reference mean may be invited to receive the remote single-session intervention.
  • Participants may enter the randomized intervention phase if they complete the single-session intervention and continue to have symptom scores at or above 1.5 standard deviations above the reference mean at follow-up.

Exclusion Criteria:

  • High suicidal risk identified during study screening or clinical assessment, requiring referral to more intensive care;
  • Elevated conduct disorder symptoms on the LUMI Global conduct disorder subscales, above the protocol-defined threshold;
  • Signs of autism spectrum disorder or intellectual disability, as assessed by the study clinician, to a degree likely to prevent the participant from benefiting from the intervention (a reported diagnosis alone is not grounds for exclusion);
  • Not completing the single-session intervention within the protocol-defined time window, unless eligibility is re-established;
  • Lack of the language ability, digital access, or connectivity needed to participate in study procedures; or
  • Not providing required consent or assent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 12-Session Telehealth Cognitive Behavioral Therapy

Participants with persistent elevated symptoms after the initial assessment and single-session intervention will receive a structured 12-session cognitive behavioral therapy intervention delivered remotely by trained providers. The intervention will address the participant's predominant symptom domain, including anxiety, depression, or disruptive behavior, as appropriate for the participant's age and presentation. Sessions may involve the participant, the primary caregiver, or both. Participants will complete follow-up assessments at approximately 4 weeks, 12 weeks, and 6 months after randomization.

Participants with persistent elevated symptoms after the initial assessment and single-session intervention will receive 12 structured cognitive behavioral therapy sessions delivered remotely by trained providers. The protocol will address the participant's predominant symptom domain, including anxiety, depression, or disruptive behavior, as appropriate for age and clinical presentation. Sessions may involve the participant, the primary caregiver, or both.

Experimental: 4-Session Telehealth Cognitive Behavioral Therapy

Participants with persistent elevated symptoms after the initial assessment and single-session intervention will receive a structured 4-session cognitive behavioral therapy intervention delivered remotely by trained providers. The intervention will address the participant's predominant symptom domain, including anxiety, depression, or disruptive behavior, as appropriate for the participant's age and presentation. Sessions may involve the participant, the primary caregiver, or both. Participants will complete follow-up assessments at approximately 4 weeks, 12 weeks, and 6 months after randomization.

Participants with persistent elevated symptoms after the initial assessment and single-session intervention will receive 4 structured cognitive behavioral therapy sessions delivered remotely by trained providers. The protocol will address the participant's predominant symptom domain, including anxiety, depression, or disruptive behavior, as appropriate for age and clinical presentation. Sessions may involve the participant, the primary caregiver, or both.

Active Comparator: Enhanced Psychoeducational Materials

Participants with persistent elevated symptoms after the initial assessment and single-session intervention will receive enhanced psychoeducational materials without therapist-delivered cognitive behavioral therapy. Materials will include videos and short texts addressing mental health symptoms and coping strategies. Participants will complete follow-up assessments at approximately 4 weeks, 12 weeks, and 6 months after randomization. Participants may continue to receive usual care and referrals throughout the study.

Participants randomized to the active comparator group will receive more intensive psychoeducational materials without therapist-delivered cognitive behavioral therapy. The materials will include videos and short texts addressing mental health symptoms, emotional well-being, and coping strategies. Participants may continue usual care and referrals throughout the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment Response at 12 Weeks After Randomization
Time Frame: 12 weeks after randomization

Proportion of participants with a reduction of at least 50% in the symptom score for the predominant clinical domain from the start of the randomized intervention phase to 12 weeks after randomization. Anxiety symptoms will be measured using the RCADS-25 Anxiety subscale, depressive symptoms using the RCADS-25 Depression subscale, and disruptive behavior using the SNAP-IV Oppositionality items. For participants aged 6-11 years, caregiver report will be used. For participants aged 12-18 years, caregiver and adolescent self-report will be collected, and participants will be classified as responders if either informant demonstrates at least a 50% reduction.

12 weeks after randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants for Whom the Single-Session Intervention Is Sufficient
Time Frame: 1 to 2 weeks after the single-session intervention

Percentage of participants who received the single-session intervention (SSI) whose overall 20-item LUMI (Library of Universal Mental Health Instruments) Screener score falls below 1.5 SD above the reference mean, and who therefore do not require stepped-up care. The percentage scoring below 0.75 SD above the reference mean will also be reported.

1 to 2 weeks after the single-session intervention
Symptom Response at 4 Weeks and 6 Months
Time Frame: 4 weeks and 6 months after randomization

Proportion with ≥50% symptom reduction from randomization.

4 weeks and 6 months after randomization
Remission at 12 Weeks
Time Frame: 12 weeks after randomization

Proportion with a domain-specific T-score below 55.

12 weeks after randomization
Number of Participants With Reliable Improvement, No Reliable Change, or Reliable Deterioration
Time Frame: From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization

Clinical change classified with the Reliable Change Index (Jacobson & Truax, 1991) on the participant's primary outcome measure: Revised Child Anxiety and Depression Scale, 25-item version (RCADS-25) Anxiety subscale (range 0 to 45), RCADS-25 Depression subscale (range 0 to 30), or Swanson, Nolan, and Pelham Questionnaire, Version IV (SNAP-IV) Oppositionality items (range 0 to 24). Higher scores indicate worse symptoms. Change is calculated from the randomization assessment.

From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization
Change in RCADS-25 Anxiety Subscale Score
Time Frame: From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization

Change in the Revised Child Anxiety and Depression Scale, 25-item version (RCADS-25) Anxiety subscale score among participants whose primary domain is anxiety. The subscale has 15 items rated 0 (never) to 3 (always); total range 0 to 45. Higher scores indicate worse anxiety symptoms.

From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization
Change in LUMI Functioning Score
Time Frame: Baseline, 1 to 2 weeks after the single-session intervention, and 4 weeks, 12 weeks, and 6 months after randomization

Change in the Library of Universal Mental Health Instruments (LUMI) Functionality score. The 7 items assess how difficult it was in the past 30 days to communicate, move around, take care of oneself, do activities at home, do school or work activities, do fun or meaningful activities, and get along with people. Each item is rated from 1 (very easy) to 5 (very difficult or cannot do it); the score is the mean of answered items, range 1 to 5. Higher scores indicate worse functioning. Caregiver report for ages 6 to 11; caregiver report and self-report for ages 12 to 18.

Baseline, 1 to 2 weeks after the single-session intervention, and 4 weeks, 12 weeks, and 6 months after randomization
Non-Inferiority of 4-Session CBT
Time Frame: 12 weeks after randomization

Comparison of 4-session versus 12-session CBT using a 25-percentage-point non-inferiority margin.

12 weeks after randomization
Percentage of Participants With at Least 50% Symptom Reduction, by Intervention Protocol
Time Frame: 12 weeks after randomization

Percentage of participants with at least a 50% reduction in the primary outcome score from randomization, reported separately for each intervention protocol: child anxiety and adolescent anxiety (RCADS-25 Anxiety subscale), adolescent depression (RCADS-25 Depression subscale), and child disruptive behavior (SNAP-IV Oppositionality items). This is an exploratory analysis; the trial is not powered to detect differences between protocols.

12 weeks after randomization
Mean Score on the Study Satisfaction Questionnaire
Time Frame: 1 to 2 weeks after the single-session intervention and 12 weeks after randomization

Participant and caregiver satisfaction measured with a questionnaire developed for this study (positive experience items, e.g., feeling welcomed, listened to, and helped by the therapist). Each item is rated from 1 (not at all) to 5 (extremely); the score is the mean of answered items, range 1 to 5. Higher scores indicate greater satisfaction.

1 to 2 weeks after the single-session intervention and 12 weeks after randomization
Change in Top Problems Assessment (TPA) Mean Severity Score
Time Frame: From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization

The participant and caregiver each identify up to three problems most important to them and rate the severity of each from 0 to 4. The score is the mean severity across the identified problems, range 0 to 4. Higher scores indicate more severe problems.

From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization
Percentage of Participants Referred to Higher-Intensity Care
Time Frame: From enrollment up to 6 months after randomization

Percentage of participants referred to more intensive mental health care, based on REDCap tracking records and therapist reports.

From enrollment up to 6 months after randomization
Percentage of Participants Reporting at Least One Therapy-Specific Adverse Effect
Time Frame: 12 weeks and 6 months after randomization

Measured with the Therapy-Specific Adverse Effects Scale: 8 statements (e.g., "My mental health is worse because of therapy"), each rated on a 5-point scale (completely agree, agree, neither agree nor disagree, disagree, completely disagree). An item is considered endorsed when rated "agree" or "completely agree". The number of endorsed items (range 0 to 8) will also be reported; higher numbers indicate more adverse effects.

12 weeks and 6 months after randomization
Change in RCADS-25 Depression Subscale Score
Time Frame: From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization

Change in the Revised Child Anxiety and Depression Scale, 25-item version (RCADS-25) Depression subscale score among participants whose primary domain is depression. The subscale has 10 items rated 0 (never) to 3 (always); total range 0 to 30. Higher scores indicate worse depressive symptoms.

From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization
Change in SNAP-IV Oppositionality Subscale Score
Time Frame: From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization

Change in the Swanson, Nolan, and Pelham Questionnaire, Version IV (SNAP-IV) Oppositionality subscale score among participants whose primary domain is disruptive behavior. The subscale has 8 items rated 0 (not at all) to 3 (very much); total range 0 to 24. Higher scores indicate worse oppositional behavior.

From randomization (1 to 2 weeks after the single-session intervention) to 4 weeks, 12 weeks, and 6 months after randomization
Net Promoter Score
Time Frame: 1 to 2 weeks after the single-session intervention and 12 weeks after randomization

Likelihood of recommending this type of care, measured with a single Net Promoter Score item: "Based on your experience with this/these session(s), on a scale from 1 to 10 where 1 is not at all and 10 is extremely, what is the likelihood of you recommending this type of care to others with similar difficulties?" Rated from 1 (not at all) to 10 (extremely). Higher scores indicate greater satisfaction.

1 to 2 weeks after the single-session intervention and 12 weeks after randomization
Percentage of Participants With Emergent Suicidal Ideation
Time Frame: 1 to 2 weeks after the single-session intervention, and 4 weeks, 12 weeks, and 6 months after randomization

Percentage of participants who answer "more than half the days" or "nearly every day" to item 9 of the Patient Health Questionnaire-9 (PHQ-9): "Over the last 2 weeks, how often have you been bothered by thoughts that you would be better off dead or of hurting yourself in some way?"

1 to 2 weeks after the single-session intervention, and 4 weeks, 12 weeks, and 6 months after randomization

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Scheduled Intervention Sessions Attended and Completed
Time Frame: From intervention initiation through completion of the assigned intervention, up to 12 weeks after randomization

Percentage of scheduled single-session intervention and CBT sessions that were attended and completed, based on REDCap tracking records.

From intervention initiation through completion of the assigned intervention, up to 12 weeks after randomization
Percentage of Randomized Participants Completing the 6-Month Follow-Up Assessment
Time Frame: From enrollment through the 6-month follow-up

Percentage of randomized participants who complete the 6-month follow-up assessment (retention), based on REDCap tracking records.

From enrollment through the 6-month follow-up
Percentage of Sessions Delivered by Videoconference Rather Than Phone Call
Time Frame: During the single-session intervention and the randomized intervention period, up to 12 weeks after randomization

Percentage of single-session intervention and CBT sessions conducted by videoconference rather than phone call, based on Thinkific platform metadata, REDCap records, and counsellor session logs.

During the single-session intervention and the randomized intervention period, up to 12 weeks after randomization
Percentage of Planned Session Content Covered, Rated From Session Recordings
Time Frame: Each single-session intervention and CBT session, up to 12 weeks after randomization

Therapist fidelity, measured as the percentage of planned core session content covered, rated by structured review of session recordings using the protocol adherence checklist.

Each single-session intervention and CBT session, up to 12 weeks after randomization
Percentage of Participants Rating the Intervention as Helpful
Time Frame: Immediately after the single-session intervention and 12 weeks after randomization

Percentage of participants and caregivers who answer "helped a lot" or "helped a little bit" to the perceived impact item of the study Satisfaction Questionnaire ("Overall, how did the session(s) with the therapist affect the difficulties you/your child was experiencing?").

Immediately after the single-session intervention and 12 weeks after randomization
Percentage of Sessions Left Incomplete Due to Platform, Device, or Connectivity Problems
Time Frame: During the single-session intervention and the randomized intervention period, up to 12 weeks after randomization

Percentage of single-session intervention and CBT sessions that could not be completed because of platform, device, or internet connectivity problems, based on Thinkific platform metadata, REDCap records, and counsellor session logs.

During the single-session intervention and the randomized intervention period, up to 12 weeks after randomization
Percentage of Adherence Checklist Items Completed, Therapist Self-Report
Time Frame: Each single-session intervention and CBT session, up to 12 weeks after randomization

Therapist adherence, measured as the percentage of protocol adherence checklist items the therapist reports as completed after each session.

Each single-session intervention and CBT session, up to 12 weeks after randomization
Percentage of Participants Rating the Intervention as Culturally Appropriate
Time Frame: Immediately after the single-session intervention and 12 weeks after randomization

Percentage of participants and caregivers who rate the study Satisfaction Questionnaire item "The language and examples used in therapy felt appropriate for my (our) context" as "a lot" or "extremely" (5-point scale from "not at all" to "extremely").

Immediately after the single-session intervention and 12 weeks after randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Carrie Brooke-Sumner, PhD, Medical Research Council, South Africa
  • Principal Investigator: Luis Augusto Rohde, MD, PhD, Hospital de Clinicas de Porto Alegre
  • Study Director: Giovanni Abrahão Salum, MD, PhD, Hospital de Clinicas de Porto Alegre
  • Study Director: Zeina Mneimneh, PhD, MS, MPH, Child Mind Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

October 1, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 97982426.8.0000.5327

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data underlying the study results may be shared. Direct identifiers, contact information, audio or video recordings, and information that could reasonably identify participants will not be shared. Data from Brazil and South Africa may be combined for collaborative analyses.

IPD Sharing Time Frame

De-identified IPD and supporting information will become available after publication of the primary study results and completion of applicable ethics, governance, and data-transfer requirements. There is no planned end date for availability, subject to continued availability of the secure repository and applicable regulations.

IPD Sharing Access Criteria

Access may be granted to qualified researchers who submit a scientifically justified research proposal and agree to applicable ethics requirements, institutional approvals, data-use restrictions, and confidentiality obligations. Access will be limited to de-identified IPD and the approved supporting information through a secure, controlled-access repository or data-transfer process.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.